Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with myeloma achieving early MRD-negative status after induction...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiahui, Yan, Wenqiang, Fan, Huishou, Xu, Jingyu, Li, Lingna, Du, Chenxing, Mao, Xuehan, Yan, Yuting, Xu, Yan, Sui, Weiwei, Deng, Shuhui, Yi, Shuhua, Anderson, Kenneth C., Qiu, Lugui, Zou, Dehui, An, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481879/
https://www.ncbi.nlm.nih.gov/pubmed/37680953
http://dx.doi.org/10.1158/2767-9764.CRC-23-0185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481879/
https://www.ncbi.nlm.nih.gov/pubmed/37680953
http://dx.doi.org/10.1158/2767-9764.CRC-23-0185

Ejemplares similares